Dr. Christopher J. Logothetis, MD

  • Houston, TX
  • Medical oncologist
NPI1477654721PAC ID5496949018
Medicare services, 2024
407
Medicare patients, 2024
224
Part D claims, 2024
51
Publications
412
Clinical trials
13
Practice address
1515 Holcombe Blvd, Houston, TX 77030
Professional email
Get professional email
Personal email
Get personal email
Mobile number
Get mobile number
Social profiles

Primary practice

Find Dr. Logothetis' professional email, personal email and mobile number

Dmand AI checks each channel through healthcare-specific waterfall enrichment. See what is on file with a free account, with practice phones, licenses and affiliations.

View contacts for free

Dr. Christopher J. Logothetis is a medical oncologist in Houston, Texas

Dr. Logothetis practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Logothetis' NPI, 1477654721, was assigned on September 26, 2006. Dr. Logothetis graduated from University of Athens in 1974. Dr. Logothetis holds Texas license F2328.

NPI and contact details
Medicare PAC ID
5496949018
NPI enumeration date
September 26, 2006
NPI status
Active
Accepts Medicare assignment
Yes
Offers telehealth
Yes
Professional email
Get email
Personal email
Get email
Mobile number
Get number
Sex
Male
Estimated age
78
Medical school graduation
1974

Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; Dmand AI Affiliation Data; and Doctors and Clinicians National Downloadable File (CMS)

Dr. Christopher J. Logothetis practices at The University of Texas MD Anderson Cancer Center in Houston, Texas

Dr. Logothetis' primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Source: Dmand AI Affiliation Data

Dr. Christopher J. Logothetis is affiliated with 1 site of care and 1 medical group

Dr. Logothetis' primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Sources: Dmand AI Affiliation Data; and Dmand AI Org Hierarchy Data

Dmand AI tracks the EHR system at Dr. Christopher J. Logothetis' practice

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Logothetis practices. Vendor and product names are available with a free account.

EHR by site
SiteEHR vendor and product
The University of Texas MD Anderson Cancer CenterAvailable with a free account

Source: Dmand AI Technology Install Data

For health IT teams

See the EHR and IT leaders at every hospital where Dr. Logothetis practices

Dmand AI maps EHR vendors, IT decision makers and buying committees across The University of Texas System and 6.2K+ hospitals, with verified contacts in the same login.

Dr. Christopher J. Logothetis is one of 484 medical oncologists in Texas

Medical oncology is Dr. Logothetis' primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Logothetis is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Logothetis' licenses on file in 12 states: Texas, Florida, Michigan, Arizona, Georgia, Mississippi, Oklahoma, Tennessee, Alabama, Louisiana, Washington and Illinois.

Specialties and state licenses

  • Medical oncology, TexasPrimaryLicense F2328 · 1978 to 2026 · taxonomy 207RX0202X
  • Florida licenseSince 2021
  • Michigan license
  • Arizona license2023 to 2027
  • Georgia license2023 to 2026
  • Mississippi license2023 to 2026
  • Oklahoma license2020 to 2026
  • Tennessee license2023 to 2026
  • Alabama license2023 to 2025
  • Louisiana license2023 to 2025
  • Washington license2023 to 2025
  • Illinois license1975 to 1982

Clinical focus

Dmand AI lists colorectal cancer, lymphoma and prostate cancer among the conditions Dr. Logothetis treats.

Medical oncologists near Dr. Logothetis

Counts of medical oncologists with a Dmand AI profile, by place and practice. Each opens the list.

Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Peer Benchmarks

Dr. Christopher J. Logothetis billed Medicare for 407 services in 2024

CMS data shows 407 Medicare services from Dr. Logothetis across 4 procedure codes in 2024, for 224 Medicare patients. Medicare paid $25,469 for them.

Medicare services, 2024407
Medicare patients224
Paid by Medicare$25,469
Procedure codes4

Dr. Logothetis' Medicare services by type, 2023 to 2024

  • 2023
  • 2024
Office and hospital visits
2023: 4702024: 40713%

Where Dr. Logothetis' Medicare services took place, 2024

  • In an office25061%
  • In a facility15739%

Dr. Logothetis compared with the Texas median for medical oncologists, 2024

  • Dr. Logothetis
  • Texas median
Medicare services
407vs 73645% below
Medicare patients
224vs 20012% above
Part D claims
12vs 33496% below

Medians across 448 medical oncologists in Texas with Dmand AI profiles that report each measure.

Dr. Logothetis' most billed Medicare procedure codes, 2024

CMS publishes codes billed for 11 or more Medicare patients. Each label is the code family; CPT descriptions are licensed by the AMA.

See all procedures by Dr. Logothetis

Need commercial claims for Dr. Logothetis?

Medicare shows one payer. Book a meeting to get commercial claims data for Dr. Logothetis and other medical oncologists in Texas.

Book a meeting

Sources: Medicare Physician & Other Practitioners - by Provider and Service (CMS), 2024 data; and Dmand AI Peer Benchmarks

Dr. Christopher J. Logothetis treated 224 Medicare patients in 2024, average age 76

CMS counts 224 Medicare patients who saw Dr. Logothetis in 2024. The largest group is 75 to 84, with 97 patients. 75% of them have cancer, and 75% have high cholesterol. Their average risk score is 1.70, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Logothetis' median patient age at 77, with 1% women.

Medicare patients, 2024224
Average age76
Average risk score1.70

Dr. Logothetis' Medicare patients by age, 2024

CMS leaves out age groups with fewer than 11 patients.

Chronic conditions among Dr. Logothetis' Medicare patients, 2024

  1. Cancer75%
  2. High cholesterol75%
  3. High blood pressure74%
  4. Arthritis46%
  5. Ischemic heart disease40%
  6. Atrial fibrillation21%
  7. Chronic kidney disease19%
  8. Diabetes19%

Share of Medicare patients with each condition. A patient can have several.

Dr. Logothetis' patients across all payers

Dmand AI patient panel data covers Medicare, Medicaid and commercial patients.

Patient panel by age, all payers

Median age 77

Patient panel by sex, all payers

  • Women1%
  • Men98%

Sources: Dmand AI Patient Panel Data; and Medicare Physician & Other Practitioners - by Provider (CMS), 2024 data

Dr. Christopher J. Logothetis wrote 51 Medicare Part D claims in 2024

In 2024, Dr. Logothetis wrote 51 Medicare Part D claims for 18 patients. 67% of them were for generic drugs. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $138 in total drug cost. In 2023, CMS named 26 claims across 1 drug.

Part D claims, 202451
Drugs named by CMS1
Total drug cost$138
Part D patients18

Dr. Logothetis' Part D claims by kind of drug, 2024

  • Generic34 claims67%
  • Brand-name17 claims33%

Dr. Logothetis' most prescribed drugs by claims, 2024

CMS names a drug when it has 11 or more claims. Share is of the claims for drugs CMS names.

Part D claims for drugs CMS names, 2023 to 2024

  • 2023
  • 2024
Claims for drugs CMS names
2023: 262024: 1254%

Drugs named by CMS: 1 in 2024, 1 in 2023.

See all prescribing by Dr. Logothetis

Sources: Medicare Part D Prescribers - by Provider and Drug (CMS), 2024 data, released May 6, 2026; and Medicare Part D Prescribers - by Provider (CMS), 2024 data

Dr. Christopher J. Logothetis scored 84 out of 100 in Medicare's MIPS program for 2024

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Logothetis for performance year 2024, reported as part of a group. Dr. Logothetis accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Logothetis as offering telehealth.

Accepts Medicare assignment
Yes
Offers telehealth
Yes

Dr. Logothetis' MIPS scores, performance year 2024

  • 84of 100Final score
  • 70.8of 100Quality
  • 100of 100Promoting Interoperability
  • 40of 100Improvement Activities
  • 68of 100Cost

Each score is out of 100. The final score weighs the categories CMS scored for this clinician.

Sources: Doctors and Clinicians National Downloadable File (CMS); and Clinician Public Reporting: Overall MIPS Performance (CMS), 2024 data, released September 10, 2026

For MedTech and pharma teams

Find medical oncologists like Dr. Logothetis by procedure volume and prescribing

Filter 7.4M+ HCPs by Medicare procedures, Part D drugs and Open Payments history, then reach them with verified contacts in one login.

Dr. Christopher J. Logothetis has 412 publications on record

Dmand AI links 412 papers to Dr. Logothetis, published from 2002 to 2025. 2016 was the busiest year, with 26. The most frequent topics are Prostatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Bone Neoplasms. Dr. Logothetis has published most often in J Clin Oncol. Dr. Logothetis' most frequent co-authors are Eleni Efstathiou, MD, Jeri Kim, MD and Ana M. Aparicio.

Papers412
Years published2002 to 2025

Dr. Logothetis' papers by year, 2016 to 2025

Topics Dr. Logothetis writes about most

  • Prostatic Neoplasms
  • Antineoplastic Combined Chemotherapy Protocols
  • Bone Neoplasms
  • Antineoplastic Agents
  • Doxorubicin
  • Disease Progression
  • Neoplasm Metastasis
  • Prostate-Specific Antigen

Dr. Logothetis' most frequent co-authors

Recent publications by Dr. Logothetis

See all 412 publications and co-authors

See who Dr. Logothetis researches with

Physician Network Discovery turns co-authorship, shared hospitals and shared groups into a map of who Dr. Logothetis works with, so you can find a warm path to the right medical oncologists.

How network discovery works

Sources: PubMed (National Library of Medicine); and Dmand AI Research Linkage

Dr. Christopher J. Logothetis has worked on 13 clinical trials

Dmand AI links Dr. Logothetis to 13 clinical trials, 8 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Prostatic Neoplasms, Prostatic Diseases and Neoplasm Metastasis. M.D. Anderson Cancer Center sponsors the most, 9.

Clinical trials with Dr. Logothetis by phase

  1. 2Phase 1: 2 trials
  2. 2Phase 1/2: 2 trials
  3. 8Phase 2: 8 trials
  4. NonePhase 3: no trials
  5. NonePhase 4: no trials

Conditions in Dr. Logothetis' trials

  • Prostatic Neoplasms
  • Prostatic Diseases
  • Neoplasm Metastasis
  • Neoplastic Processes

Investigators on the most trials with Dr. Logothetis

Recent clinical trials with Dr. Logothetis

See all 13 clinical trials and co-investigators

Sources: Dmand AI Research Linkage; and ClinicalTrials.gov (National Library of Medicine)

Dr. Christopher J. Logothetis received $110,232 in industry payments from 2016 to 2025

CMS Open Payments shows 149 general payments to Dr. Logothetis from 17 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 80% of the total. Sanofi and Genzyme US Companies paid the most, $31,270. It also lists 9 research payments totaling $10,769 from 2016 to 2025.

General payments to Dr. Logothetis by program year, 2016 to 2025

General payments to Dr. Logothetis by kind, 2016 to 2025

$110.2Kin total
  • Consulting fees$88,68680%
  • Travel and lodging$9,8799%
  • Honoraria$6,7656%
  • Food and beverage$4,6114%
  • Education$2910%

Companies that paid Dr. Logothetis the most, 2016 to 2025

Share is of all general payments to this clinician.

See all payments to Dr. Logothetis

Source: Open Payments (CMS), 2025 data, released July 7, 2026

Dr. Christopher J. Logothetis has 4 awards and honors on record

Dmand AI lists 4 awards for Dr. Logothetis, most recently America's Top Doctors in 2014.

Awards and honors for Dr. Logothetis

  1. 2014
    • America's Top Doctors
  2. 2013
    • America's Top Doctors for Cancer
    • Top Doctors:SE Texas
  3. Undated
    • Super Doc

Source: Dmand AI Professional Profile Data

Dr. Christopher J. Logothetis graduated from University of Athens

Dr. Logothetis graduated from University of Athens in 1974.

  1. Medical schoolUniversity of Athens
  2. Board certified in internal medicineAmerican Board of Internal Medicine
  3. Board certified in medical oncologyAmerican Board of Internal Medicine

Source: Dmand AI Professional Profile Data

Dr. Christopher J. Logothetis accepts plans from 9 insurance carriers

Dr. Logothetis is in network with 9 carriers, including Aetna, Elevance and United Healthcare. PPO plans come from the most carriers, 6. Check the plan with the practice before a visit.

  • Aetna
  • Elevance
  • United Healthcare
  • Blue Cross Blue Shield of Michigan
  • Aspirus Health Plan
  • Blue Cross and Blue Shield of Kansas City
  • Cigna
  • CMS Medicare
  • +1 more carriersWith a free account

Plan types Dr. Logothetis accepts, by number of carriers

  1. PPO6
  2. POS5
  3. HMO4
  4. Medicare4
  5. EPO3

Source: Dmand AI Insurance Network Data

Sources for Dr. Christopher J. Logothetis's profile data

Sources for the data on this page
Data on this pageSource
NPI, name, sex, specialty and licensesNPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Professional Profile Data
Practice locations and phoneDmand AI Affiliation Data
Primary practice, affiliations and health systemDmand AI Affiliation DataDmand AI Org Hierarchy Data
Medicare services and procedure codesMedicare Physician & Other Practitioners - by Provider and Service (CMS) (opens in a new tab)
State medians for the same specialtyDmand AI Peer Benchmarks
Medicare patients and the all-payer patient panelDmand AI Patient Panel DataMedicare Physician & Other Practitioners - by Provider (CMS) (opens in a new tab)
Part D prescribingMedicare Part D Prescribers - by Provider and Drug (CMS) (opens in a new tab)Medicare Part D Prescribers - by Provider (CMS) (opens in a new tab)
MIPS scores, telehealth, assignment and procedure percentilesDoctors and Clinicians National Downloadable File (CMS) (opens in a new tab)Clinician Public Reporting: Overall MIPS Performance (CMS) (opens in a new tab)
Publications, topics and co-authorsPubMed (National Library of Medicine) (opens in a new tab)Dmand AI Research Linkage
Clinical trials and co-investigatorsDmand AI Research LinkageClinicalTrials.gov (National Library of Medicine) (opens in a new tab)
Industry paymentsOpen Payments (CMS) (opens in a new tab)
Awards and committee rolesDmand AI Professional Profile Data
Training, board certification and membershipsDmand AI Professional Profile Data
Insurance carriers and plan typesDmand AI Insurance Network Data
EHR at each practice siteDmand AI Technology Install Data
Similar physiciansDmand AI Affiliation Data

Data last refreshed October 2026Report an inaccuracyRemove my information

FAQ

Frequently asked questions about Dr. Christopher J. Logothetis

Spotted something out of date? Email hello@dmand.ai and we will check the record. Contact details live in the free trial.

What is Dr. Christopher J. Logothetis' NPI number?

Dr. Christopher J. Logothetis' NPI number is 1477654721. It was assigned on September 26, 2006, and it is active in the NPI Registry.

What kind of doctor is Dr. Christopher J. Logothetis?

Dr. Christopher J. Logothetis is a medical oncologist in Houston, Texas. The primary specialty in the NPI Registry is Medical Oncology Physician (taxonomy code 207RX0202X).

Where does Dr. Christopher J. Logothetis practice?

Dr. Logothetis practices at 1515 Holcombe Blvd, Houston, TX 77030. Dr. Logothetis' primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

What is Dr. Christopher J. Logothetis' medical license number?

Dr. Logothetis holds Texas license F2328, one of the licenses on file in 12 states.

Which states has Dr. Christopher J. Logothetis been licensed in?

Dmand AI has state licenses on file for Dr. Logothetis in Texas (1978 to 2026), Florida (since 2021), Michigan, Arizona (2023 to 2027), Georgia (2023 to 2026), Mississippi (2023 to 2026), Oklahoma (2020 to 2026), Tennessee (2023 to 2026), Alabama (2023 to 2025), Louisiana (2023 to 2025), Washington (2023 to 2025) and Illinois (1975 to 1982).

Which hospitals is Dr. Christopher J. Logothetis affiliated with?

Dr. Logothetis practices at The University of Texas MD Anderson Cancer Center in Houston, Texas.

What medical group is Dr. Christopher J. Logothetis part of?

Dr. Logothetis is linked to Physicians Referral Service.

Does Dr. Christopher J. Logothetis accept Medicare?

Yes. CMS data shows Dr. Logothetis billed Medicare for 407 services in 2024, and Dr. Logothetis accepts Medicare assignment.

Does Dr. Christopher J. Logothetis offer telehealth?

Yes. The CMS Doctors and Clinicians file lists Dr. Logothetis as offering telehealth services.

What is Dr. Christopher J. Logothetis' MIPS score?

Dr. Logothetis' MIPS final score for performance year 2024 is 84 out of 100, reported as part of a group.

Show 10 more questionsShow fewer questions

How many Medicare patients does Dr. Christopher J. Logothetis see?

CMS counts 224 Medicare patients who saw Dr. Logothetis in 2024, with an average age of 76.

Is Dr. Christopher J. Logothetis board certified?

Yes. Dr. Logothetis is board certified in internal medicine by the American Board of Internal Medicine.

What services does Dr. Christopher J. Logothetis bill to Medicare?

In 2024, Dr. Logothetis' most billed Medicare services were office visit, established patient (99214), care management and other visits (99441) and office visit, established patient (99215).

Where did Dr. Christopher J. Logothetis go to medical school?

Dr. Logothetis graduated from University of Athens in 1974.

What drugs does Dr. Christopher J. Logothetis prescribe most?

In 2024 Medicare Part D data, Dr. Logothetis' most prescribed drugs by claims were Prednisone.

Has Dr. Christopher J. Logothetis received payments from drug or device companies?

CMS Open Payments shows $110,232 in general payments to Dr. Logothetis from 17 companies from 2016 to 2025. The largest total came from Sanofi and Genzyme US Companies.

How long has Dr. Christopher J. Logothetis been practicing?

Dr. Logothetis graduated from medical school in 1974, 52 years ago.

Does Dr. Christopher J. Logothetis do research?

Dmand AI links 412 publications to Dr. Logothetis, published from 2002 to 2025. Dr. Logothetis has worked on 13 clinical trials.

Who does Dr. Christopher J. Logothetis publish with?

Dr. Logothetis' most frequent co-authors are Eleni Efstathiou, MD (42 shared papers), Jeri Kim, MD (29 shared papers) and Ana M. Aparicio (24 shared papers).

What insurance does Dr. Christopher J. Logothetis accept?

Dr. Logothetis is in network with 9 carriers, including Aetna, Elevance and United Healthcare. PPO plans come from the most carriers, 6. Check the plan with the practice before a visit.

Selling to medical oncology practices?

See medical oncologists in Texas by site of care and group

Find the practices, groups and hospitals they work with, and the right people to contact at each.

  • 30 days free
  • Self-serve
  • No credit card

Cookie settings

Turn each category on or off. Your choice is kept for 12 months and you can change it here at any time.

Necessary

Always on. Sign-in, security, downloads you asked for, your cookie choice, and the page that led to a signup.

View cookies (6)
  • dm_consentDmand AI. Your cookie choices and whether your browser sent a Global Privacy Control signal. 12 months.
  • dm_ft, dm_ltDmand AI. The first and the latest page you arrived on, with the date, so a signup is credited to the page that worked. 90 days, 30 days.
  • dm_fs, dm_lsDmand AI. The first and the latest source of a visit (a search engine, a campaign or the site that linked here). 90 days, 30 days.
  • dm_dl, dm_dl_okDmand AI. After you give an email address for a download, lets you download files without being asked again. 30 days.
  • Session and CSRF cookiesDmand AI (app.dmand.ai). Sign-in and form protection in the application. Session.
  • __cf_bm, cf_clearanceCloudflare. Tells people from automated traffic and keeps the site available. 30 minutes; cf_clearance while a security check is valid.

Analytics

On unless you turn it off. How pages are used, in aggregate, and recordings of how pages are used.

View cookies (6)
  • Google Tag ManagerGoogle. Loads the analytics and marketing tags that are on. Sets no cookie of its own and does not load when both categories are off. n/a.
  • _ga, _ga_<container-id>Google Analytics 4. Visits and page views in aggregate on dmand.ai. 2 years.
  • _clck, _clskMicrosoft Clarity. Recordings and heatmaps of how pages are used, with form fields masked. 1 year, 1 day.
  • CLID, MUID, ANONCHK, MR, SMMicrosoft (clarity.ms). Set by Microsoft when Clarity loads, to recognize a browser across sites that use Clarity. Up to 1 year.
  • None (cookieless)Ahrefs Analytics. Page views in aggregate. n/a.
  • ph_<project>_posthogPostHog. Product usage, errors and performance in app.dmand.ai, used to fix bugs and improve features. 365 days.

Marketing

On unless you turn it off, and always off when your browser sends a Global Privacy Control signal. A visitor identification service tells our sales team which companies and people visit.

View cookies (6)
  • _reb2buid, _reb2butkRB2B. Recognizes a returning browser for visitor identification. 360 days, 1 year.
  • _reb2bgeoRB2B. The location used to decide whether a visit can be identified. 20 days.
  • _reb2brefRB2B. The page or site that referred the visit. 15 days.
  • _reb2bfxf, _reb2btd, _reb2bliRB2B. Links the visit to an identified business profile. 1 month.
  • _reb2bresolveRB2B. Holds a match while it is being resolved. 2 days.
  • _reb2sessionID, _reb2bloadedRB2B. The current visit, and a guard against loading the script twice. 30 minutes, 1 second.

Functional

On unless you turn it off. Remembers choices such as a collapsed section.

View cookies (none today)